BrainSpec

The team formed at an iHub brainstorming session at Brigham and Women’s Hospital. Collaborators include radiologists, oncologists, neurologists and neurosurgeons at Brigham and Women’s Hospital and Massachusetts General Hospital.

Magnetic Resonance Spectroscopy (MRS) provides a ‘virtual biopsy’ by measuring the concentrations of chemicals in the brain.

BrainSpec says its privacy policy covers information collected by the Website and was current as of the stated effective date. The policy may change over time.

BrainSpec signs a license agreement with the University of Minnesota Center for Magnetic Resonance Research to commercialise AutoVOI, a tool that automates brain-region selection for magnetic resonance spectroscopy. The agreement focuses on bringing the MRS automation tool to market.

Sep 2025 · Medical Device NetworkNews article

BrainSpec Core identifies previously undetected injuries in 90 percent of people with a history of mild traumatic brain injury, according to a Washington University School of Medicine study. The finding highlights the company's MRS platform as a tool for detecting brain abnormalities.

Oct 2024 · Medical Device NetworkNews article

BrainSpec received FDA clearance for BrainSpec Core, its AI-assisted magnetic resonance spectroscopy (MR spectroscopy) platform, which non-invasively measures brain chemistry. The software is cleared to assist clinicians in diagnosing neurologic disorders using MR spectroscopy as a clinical diagnostic aid.

Nov 2023 · Practical NeurologyNews article

BrainSpec announces full FDA clearance for BrainSpec Core, its AI-backed magnetic resonance spectroscopy platform. The clearance allows BrainSpec to begin using the platform for non-invasive measurement of brain chemistry.

Nov 2023 · PR NewswireNews article